Form 4: IO Biotech Director Heidi Hunter Acquires Stock Options
SEC Form 4
Director Heidi Hunter acquired stock options in IO Biotech, Inc. on June 6, 2024.
Summary
- Heidi Hunter, a director of IO Biotech, Inc., filed a Form 4 on June 7, 2024, reporting a transaction.
- On June 6, 2024, Hunter acquired 45,642 stock options with an exercise price of $1.25.
- These options vest on June 6, 2025, contingent upon continued service and accelerate fully upon a change of control.
- Following the transaction, Hunter directly owns 45,642 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.
Stakeholder Impact
- Shareholders may view the stock option grant as an incentive for the director to align their interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of stock option acquisition |
| 06/06/2025 | Vesting date for the stock options |
| 06/06/2034 | Expiration date for the stock options |
| 06/07/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.